The arrival of official JCA expert templates forces a question: who shapes the evidence request before a company ever opens its dossier? Published by the European Commission in mid-September 2026, these instruments do not invent participation rights. They fix patient, carer and clinician comment at two decisive moments in joint clinical assessment, place that comment in a public appendix, and thereby change the information climate in which health economics, market access and reimbursement decisions are prepared. This piece reflects on what that design means for pricing strategies, system dynamics and long-term value assessment across the Union.

Why the timing of voice now matters more than its volume

Under Regulation (EU) 2021/2282, assessors first draft PICOs, Member States add national needs, and those needs collapse into a consolidated assessment scope proposal. Only then do selected individuals receive the new scoping questionnaires. Their written replies feed the scope-finalisation meeting; the locked scope goes to the developer; later the same experts review the draft report and summary on a short comment form. Both rounds appear in Appendix A. Patient and carer text is anonymised. Clinician names are not given the same protection. All work runs in English within seven calendar days. Compensation follows standard Commission expert rules.

That sequence is the strategic fact. Comment arrives after national PICOs exist, yet before the company is bound. Once frozen, extra comparators, subgroup cuts and patient-relevant endpoints become dossier duties. For leaders who still treat joint assessment as a distant clinical exercise, the policy implications are easy to miss and costly to discover late.

From lived experience to binding evidence architecture

The patient and carer file spends many pages on onboarding before it asks a single question. Glossaries separate subgroups from subpopulations. A plain definition states that joint clinical assessment addresses relative effectiveness, relative safety and certainty—not price, organisation or ethics, which remain national. Prompts then steer respondents toward visibility of older people, younger adults, early-symptom groups and socio-economically disadvantaged patients; toward comparator relevance on invasiveness, convenience, travel and monitoring; and toward outcomes that capture quality of life, function, symptom burden, survivorship and late toxicity. Intervention stays locked to the European Medicines Agency claim. Outcomes are shared across PICOs, which limits endpoint multiplication.

Clinical experts answer a parallel structure with a different task: whether populations are identifiable in routine care, whether comparator lists reflect standard practice—including watchful waiting or individualised bundles—and whether requested cuts help explain differences in effect. They are told, bluntly, that the consolidated proposal serves all EU and EEA Member States, not a single national standard of care. The later report form is thinner still: a line-level log without structured prompts on certainty, indirectness or narrative fit with practice. Usefulness at that second stage will vary widely, even though national bodies will cite the final report when they reach reimbursement decisions.

Consequences for value, price and system dynamics

JCA expert templates leave pricing sovereignty untouched, yet they reshape the raw material on which value-based pricing arguments later rest. If experts place administration burden, function or late toxicity on the outcomes table, developers must evidence them. Indirect comparison plans and statistical analysis should therefore follow the joint taxonomy—shared outcomes, Member State-driven subgroups, and separate subpopulations where comparators or prognosis differ—rather than a single global label population. Budget impact models that ignore those dimensions will sit poorly beside the clinical package that national authorities receive.

System dynamics shift in quieter ways. A comparator that matters in one country but never enters the consolidated PICO, and that no expert flags, is harder to repair at HAS, G-BA, AIFA or INFARMED. Geographic diversity guides selection, yet English-only forms and a seven-day clock filter who can respond with care. Named clinicians may hesitate before describing fragile standard of care or weak comparators. Individuals may not speak for organisations, so umbrella views familiar to national HTA bodies travel only if a single respondent happens to hold them. No published rule explains how the Subgroup resolves expert input that contradicts a Member State PICO. “Made available and discussed” is process, not hierarchy. Medicinal-product coding also leaves high-risk device assessments, due from 2026, without a matched variant in this package.

The Central Lesson

The central lesson is institutional rather than technical. JCA expert templates do not merge clinical assessment with national payment. They insert structured patient and clinician judgement at the last moment it can still alter the evidence request, then record that judgement where every subsequent appraisal can see it. Organisations that file the questionnaires under compliance will meet the consequences after lock. Those that fold them into PICO design, endpoint planning, pricing strategies and Appendix A intelligence will stand on firmer ground for joint assessment and for the reimbursement decisions that follow. Clearer rules on disagreement, language access and device-specific forms remain open issues.

This reflection draws on the materials published by the European Commission (https://health.ec.europa.eu/latest-updates/three-new-templates-support-written-input-patients-carers-and-clinicians-joint-clinical-assessments-2026-09-14_en).

Frequently Asked Questions

What are JCA expert templates?

JCA expert templates are the official instruments the European Commission published in September 2026 to structure written input from patients, carers and clinicians at two fixed moments in the EU joint clinical assessment: the scoping stage and the review of the draft report. Both rounds of input are recorded in a public appendix.

Do JCA expert templates change pricing or reimbursement decisions?

Not directly. Pricing, organisation and ethics remain national competencies. The templates instead shape the evidence request — comparators, subgroups and patient-relevant outcomes — on which national HTA and pricing bodies later base their decisions.

When in the JCA timeline does expert input happen?

Expert comment arrives after Member States’ national needs are consolidated into the assessment scope proposal, but before the scope is locked and sent to the developer, and again when experts review the draft report. Responses must be completed in English within seven calendar days.